Bionomics IPO Presentation Deck

· wwwww BNC210's Rapid Onset of Action is Potentially Well-Positioned for Social Anxiety Disorder Emerging Regulatory Landscape & Unmet Need No fast-acting FDA-approved medications for as-needed treatment of SAD Benzodiazepines prescribed off-label have significant side effects of sedation, cognitive impairment and potential for addiction Growing unmet need based on improving awareness and evolving social dynamics FDA precedent on simplified public speaking challenge endpoint for acute anxiety reduction vs. placebo* Bionomics "Based on path of CNS peer proceeding with registrational Phose 3 endpoint Rapid Onset of Action with BNC210 Formulation Clinically demonstrated potential for reducing anxiety in acute treatment of GAD patients and following panic induction Observed acute anxiolytic efficacy of BNC210 similar to lorazepam without sedative properties and addiction liability Formulation potentially well-suited for acute dosing - Rapidly absorbed to high concentrations within a short period of time √ Maximum concentrations reached in -45-105 min. across the dose range Concentration ng/ml 5000- 4000- D T 2 E 161 Concentration versus Time 1200 mg tablert fasted 900 mg tablet fasted 1:8 T 10 Time (hours) 800 mg tablet fo 16 T 18 T 20 14 T

View entire presentation